869718-81-0

Basic information

• Product Name: 3,6,9,12,15,18,21,24-Octaoxapentacosan-1-amine
• Synonyms: 3,6,9,12,15,18,21,24-Octaoxapentacosan-1-amine;MPEG8-NH2;m-PEG8-amine;m-dPEG(R)8-amine;2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanamine
• CAS NO: 869718-81-0
• Molecular Formula: C₁₇H₃₇NO₈
• Molecular Weight: 383.48
• Mol File: 869718-81-0.mol

Chemical Properties

• Boiling Point: 448 °C at 760 mmHg
• Flash Point: 213.9 °C
• Appearance: /
• Density: 1.054
• Storage Temp.: -20°C
• Solubility: Soluble in Water
• PKA: 8.74±0.10(Predicted)
• CAS DataBase Reference: 3,6,9,12,15,18,21,24-Octaoxapentacosan-1-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 3,6,9,12,15,18,21,24-Octaoxapentacosan-1-amine(869718-81-0)
• EPA Substance Registry System: 3,6,9,12,15,18,21,24-Octaoxapentacosan-1-amine(869718-81-0)

Safety Data

• Hazardous Substances Data: 869718-81-0(Hazardous Substances Data)

Usage

Uses

Used in Bioconjugation:
3,6,9,12,15,18,21,24-Octaoxapentacosan-1-amine is used as a bioconjugation agent for attaching biologically active molecules, such as peptides, proteins, or drugs, to other molecules or surfaces. Its reactivity with carboxylic acids, activated NHS esters, and carbonyls allows for stable and specific conjugation.
Used in Drug Delivery Systems:
In the pharmaceutical industry, 3,6,9,12,15,18,21,24-Octaoxapentacosan-1-amine is used as a component in drug delivery systems to improve the solubility, stability, and bioavailability of therapeutic agents. The hydrophilic PEG spacer can reduce the immunogenicity and non-specific interactions of the drug, leading to enhanced circulation time and targeted delivery.
Used in Diagnostic Imaging:
3,6,9,12,15,18,21,24-Octaoxapentacosan-1-amine is used as a contrast agent or a component in the development of imaging probes for various diagnostic modalities, such as magnetic resonance imaging (MRI), computed tomography (CT), or positron emission tomography (PET). The PEG spacer can improve the stability and biocompatibility of the imaging agents, allowing for better imaging resolution and reduced side effects.
Used in Hydrogels and Tissue Engineering:
In the field of tissue engineering, 3,6,9,12,15,18,21,24-Octaoxapentacosan-1-amine is used as a component in the design and fabrication of hydrogels for tissue regeneration and repair. The hydrophilic PEG spacer can provide a favorable microenvironment for cell adhesion, proliferation, and differentiation, promoting tissue integration and healing.
Used in Surface Modification:
3,6,9,12,15,18,21,24-Octaoxapentacosan-1-amine is used for surface modification of various materials, such as nanoparticles, implants, or sensors, to enhance their biocompatibility, stability, or functionality. The PEG spacer can provide a protective layer, reducing non-specific interactions and improving the overall performance of the modified surfaces.

Upstream product

• 869718-80-9 25-azido-2,5,8,11,14,17,20,23-octaoxapentacosane 
• 25990-96-9 octaethylene glycol monomethyl ether 
• 82217-01-4 2,5,8,11,14,17,20,23-octaoxapentacosan-25-yl 4-methylbenzenesulfonate 

Downstream Products

• 1224727-98-3 C₂₇H₄₆N₂O₁₁ 

Relevant articles and documents

A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS

Provided is a conjugation of cytotoxic drug to a cell-binding molecule with a side-chain linker. It provides side-chain linkage methods of making a conjugate of a cytotoxic molecule to a cell-binding ligand, as well as methods of using the conjugate in targeted treatment of cancer, infection and immunological disorders.

CROSSLINKED POLYMER NANO-ASSEMBLIES AND USES THEREOF

The invention provides powerful methods and compositions for designing, selecting, fine-tuning and optimizing polymer nanogel and other supramolecular assemblies for various properties including, for example, particle size, density and morphology, guest l

Antioxidants Having Aromatic Structures Reacting with Superoxide

Disclosed is a method of treating diseases which are: reactive oxygen species mediated, ischemic or reperfusion-related, or T-cell mediated, including autoimmune diseases. The method is administering a therapeutically effective amount of a formulation wherein the active ingredient includes non-phenolic aromatic structures that are electron deficient and are capable of converting the superoxide radical to O2; and/or of converting superoxide radical to oxygen and hydrogen peroxide, or pharmaceutically acceptable salts of said structures. Also disclosed is a method of diagnosing and treating such diseases and conditions.

TREATMENT OF MYOPIA

The present invention relates to altering the physical and/or chemical properties of at least part of at least one tissue in the eye. In a specific embodiment, it relates to the treatment and/or prevention of myopia. An activating energy source is utilize